Novel therapeutics could offer clinicians an additional tool in developing their patient treatment plans, particularly for those with no response or resistance to existing therapies.
Researchers have identified significant and specific variations in the microbial universe of the small intestine in overweight or obese adults compared with normal-weight peers.
In patients with cirrhosis, probiotics reduce HE and improve liver function scores, quality of life, and gut flora, a systematic review and meta-analysis finds.